The study on Keap1-Nrf2-ARE signaling pathway and PLVAP changes and drug intervention in coronary endothelial cells of patients with acute ST-segment elevation myocardial infarction

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053328

Enrollment

Unknown

Registered

2021-11-19

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ST-segment elevation myocardial infarction

Interventions

Acute myocardial infarction group:No

Normal control group:No

Eligibility

Sex/Gender

All

Age

No minimum to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with acute ST-segment elevation myocardial infarction with onset <= 12 hours; 2. Aged <= 65 years; 3. Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with postoperative death endpoint events; 2. Patients with myocarditis or pericarditis; 3. Patients with acute cerebrovascular disease; 4. Patients with heart, liver and kidney insufficiency; 5. Patients with acute and chronic infectious diseases; 6. Tumor patients; 7. Patients with autoimmune diseases; 8. Patients with contraindications to CMR examination.

Design outcomes

Primary

Measure	Time frame
Nuclear factor E2-related factor 2;Plasmalemma vesicle-associated protein;Heme oxygenase-1;Infracted myocardial area;	—

Secondary

Measure	Time frame
Reactive oxygen species;Endothelins-1;Vascular endothelial growth factor;Nitric oxide;Hypoxia inducible factor-1alpha;Endothelial nitric-oxide synthase;	—

Countries

China

Contacts

Public ContactZhang Qiubing

Guangyuan Central Hospital

zqbgf715@163.com+86 15700556168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026